Good Lifestyle

When it comes tocancer drugs, the vast majority of candidates fail during clinical trials. In fact, according to the American Council for Science and Health,3.4% of oncology trials Train the approval of the United States Food and Drug Administration (FDA) or another regulatory body. This is part of what makes the amazing success of a recent test of drug drugs so impressive.

After testing an immunotherapy treatment in a small group of people with rectum stadium 2 and stage 3, the researchers found that each subject had entered a remission. Read the rest to find out more about test experts call "unprecedented" and "paradigm shift" and to find out who could benefit from this revolutionary progress.

Read this then:If this happens to you in the bathroom, check the cancer, the doctors warn.

Colorectal cancer is theThird type of most common cancer in the USA. Nearly 45,000 new cases of rectum cancer and more than 106,000 cases of colon cancer are diagnosed each year, explains the American Cancer Society.

Although the overall number of rectum cancer cases has dropped since 2013 thanks to increased screening and changes in the risk of lifestyle in older patients, cases increase at a rate of 2% each year in adults under the age of 50. The most common treatment for all stages of rectum cancer is surgery, although many patients also suffer radiotherapy and chemotherapy.

Read this then:Drinking this popular drink can triple your risk of cancer, studies say.

In a small test of 12 subjects with localized rectum cancer, researchers from the Memorial Sloan Kettering Cancer Center (MSKCC) found that an experimentalImmunotherapy treatment passed the 12 individuals in remission. After receiving eight doses of treatment for the treatment administered by IV, each of the subjects of the subjects was made undetectable by endoscopy, MRI, TEP analysis or physical exam.

"These areimmunotherapy drugs This work not by directly attacking cancer itself, but in fact doing the immune system of a person to do essentially work "Hanna Sanoff, MD, from the Cancer Center Center Center at the University of Caroline du Nord, MD, told NPR All Things.AE0FCC31AE342FD3A1346EBB1F342FCB

The study, published last weekThe New England Journal of MedicineExplains that the "inhibitor of the control point" treatment was provided every three weeks for six months in patients with localized "mesapparial repair" and deficient "and stage 3. approximately five of all Patients with rectal cancer would be considered good candidates for this particular treatment, noted Sanoff.

Although the test group is small, the treatment100% success rate Astonished even the researchers themselves. "I think this is the first time it has happened in the history of cancer", "Luis A. Diaz Jr., MD, an author of the study, saidThe New York Times.

Historically, thefive -year survival rate For localized cases of rectum cancer, was 90%, explains the American Society of Clinical Oncology (ASCO). If cancer has spread to other tissue, organs or lymph nodes, the survival rate is 73%.

However, many of those who have survived patients who undergo surgery - the most common form of treatment for rectum cancer - continue to feel serious side effects.

"In rectum cancer, it is part of the conversation we have with someone when diagnosed. We hope to be able to heal you, but unfortunately, we know that our treatments will leave you consequences that can , in fact, who changes his life, "said Sanoff. "I had patients who, after their rectal cancer, barely left the house for years - and in a few cases, even decades - due to the consequences of incontinence and the shame associated with it "Added Sanoff, who did not work on the study butwrote an editorial the accompanying person.

Given the small size of the trial, more research is necessary to confirm the results of the team and further explore possible side effects. In the wider population of patients who take control point inhibitors, three to five percent have more serious complications such as muscle weakness and difficulty chewing or swallowing, reportsThe New York Times.

Experts also expect the 100% success rate down as the treatment is tested on a wider pool of materials.

However, the results are both extraordinary and encouraging for patients who suffer from rectum cancer and the doctors who treat them. "I am incredibly optimistic," said Sanoff of the study, describing the results of "paradigm transfer".

"We have never seen anything working in 100% of people in cancer medicine," she added.

Read this then: Taking too much this supplement can ensure that your risk of dementia moves, studies the results .